ライフサイエンスコーパス: lipid-lowering agent

1 rugs [NSAIDs] or aspirin, 17 hormones, and 7 lipid-lowering agents).

2 mg/m2/d plus concomitant levothyroxine and a lipid-lowering agent.

3 l need for more effective and well tolerated lipid-lowering agents.

4 lglutaryl coenzyme A reductase and effective lipid-lowering agents.

5 umed selection biases in the prescription of lipid-lowering agents.

6 clinical investigation of ASBT inhibitors as lipid-lowering agents.

7 In 252,460 patients treated with lipid-lowering agents, 24 cases of hospitalized rhabdomy

8 in all groups, changes were manageable with lipid-lowering agents and did not warrant discontinuatio

9 included as an outcome in clinical trials of lipid-lowering agents and lifestyle modifications.

10 justment for the propensity to be prescribed lipid-lowering agents and other potential confounders, p

11 , mechanical ventilation, gastrostomy tubes, lipid-lowering agents and symptom management.

12 self-reported use of aspirin, beta-blockers, lipid-lowering agents, and their combinations in all CAD

13 torial risk reduction with statins and other lipid-lowering agents, antihypertensive therapies, and a

14 Lipid-lowering agents are known to reduce long-term mort

15 Additional lipid-lowering agents are needed to fulfill an unmet med

16 stimates of rhabdomyolysis risk with various lipid-lowering agents are not available.

17 Lipid-lowering agents are widely prescribed in the Unite

18 ntion, including aspirin, beta-blockers, and lipid-lowering agents, are underused in these women, esp

19 Subsequent use of statin, other lipid-lowering agents, aspirin, and angiotensin-converti

20 blocker, and 20% to 25% were not receiving a lipid-lowering agent at 90 days after the index test.

21 her potential confounders, prescription of a lipid-lowering agent at discharge remained associated wi

22 ercury II-Compare the Efficacy and Safety of Lipid Lowering Agents Atorvastatin and Simvastatin With

23 Each of the lipid-lowering agents available today can cause myopathy

24 Further trials of lipid-lowering agents beyond statins will be required in

25 ant differences in other lipids, BMI, use of lipid lowering agents, blood pressure, or smoking status

26 ibility that S1P inhibitors may be effective lipid-lowering agents, but they suggest that nearly comp

27 Although most other lipid-lowering agents can be used safely with statins in

28 The only lipid-lowering agent currently available that specifical

29 The reduction of coronary events by lipid-lowering agents despite only modest luminal change

30 The recent FIELD study demonstrated that the lipid-lowering agent fenofibrate significantly reduces t

31 et drugs, beta-blockers, ACE inhibitors, and lipid-lowering agents, have proven efficacy in reducing

32 equently, thyromimetic drugs hold promise as lipid-lowering agents if adverse effects can be avoided.

33 alpha ligand that has been widely used as a lipid-lowering agent in the treatment of hypertriglyceri

34 IV infection include lifestyle modification, lipid-lowering agents, insulin sensitizers, and treatmen

35 e implications regarding the clinical use of lipid-lowering agents, like fibric acids, which can acti

36 and older: all individuals who had received lipid-lowering agents (LLAs); all individuals with a cli

37 Lipid-lowering agents may not reduce the incidence of ac

38 Treatment with lipid-lowering agents may reduce risk of death following

39 s Heart Study participants who were using no lipid-lowering agent (n = 2,124) or using only a statin

40 te coronary syndromes who were discharged on lipid-lowering agents (n=3653) with those who were not (

41 reviously: greater use of and more effective lipid-lowering agents, no significant weight gain, no di

42 A) reductase inhibitors (statins) and other lipid-lowering agents on dementia.

43 Bexarotene patients also received lipid-lowering agents on or before day 1.

44 ted to the lipid pathway, and the effects of lipid-lowering agents on reducing the incidence of OA.

45 in those who used systemic corticosteroids, lipid-lowering agents, or testosterone; those who exerci

46 or antiplatelets/anticoagulants (p<0.05) and lipid-lowering agents (p<0.001) and were maintained at 1

47 rs, and antithrombotic agents in addition to lipid-lowering agents, reduce events, and this may be at

48 atients with type 2 diabetes, treatment with lipid-lowering agents reduces cardiovascular risk.

49 The advent of the statin class of lipid-lowering agents represented a major advance, becau

50 Combination therapy with lipid-lowering agents that act via a complementary pathw

51 In patients treated with lipid-lowering agents, the vasodilator response to acety

52 4, the British government decided to allow a lipid-lowering agent to be sold as an over-the-counter m

53 emission tomography, changes in aspirin and lipid-lowering agent use was greater after computed tomo

54 Treatment with lipid-lowering agents was associated with lower crude mo

55 ry of medicines, including statins and other lipid-lowering agents, was collected at both assessments

56 n of antihypertensive agents, diuretics, and lipid lowering agents were also studied.

57 that compared statins with another statin or lipid-lowering agent were excluded.

58 G-CoA) reductase, also known as statins, are lipid-lowering agents widely used in the prevention of c

59 Guidelines recommend combining additional lipid-lowering agents with a complementary mode of actio